Home › NDC Lookup › Ingredients › Carisoprodol › 00591-5513-01
⚪image loading
(from DailyMed)

Carisoprodol 350 mg Tablet, 100-count — NDC 0591-5513-01 (Billing 00591-5513-01)

by Actavis Pharma, Inc. · 100 TABLET in 1 BOTTLE

This is a package of 100 tablets of Carisoprodol 350 mg Tablet from Actavis Pharma, Inc., no longer marketed (first marketed Nov 1987), no longer in the FDA NDC Directory; retail pharmacies pay about $0.0712 per tablet (NADAC). It is the main listing for this product, which comes in 4 package sizes.

NDC 00591-5513-01
🏷️ FDA NDC (as labeled) 0591-5513-01 billing pads the labeler segment with a zero
This package
Contains100-count Cost per ea$0.0712 NADAC Per package$7.12 / 100 tablets Pack sizes4 compare ↓
Main listing for product 0591-5513 · Also comes in: 500 tablets 0591-5513-05 1000 tablets 0591-5513-10 22200 tablets 0591-5513-00
Discontinued CIV ⚠ Discontinued by firm ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0591-5513-01 alone.

Record
FDA NDC Directory package listing · Drug for further processing
Code segments
0591 labeler · 5513 product · 01 package
Listing certified through
Dec 31, 2026
Billing quantity
100 EA per package
Barcode (UPC-A, from the NDC)
3 0591551301 1
FDA record last changed
Jul 24, 2026
⚠️
Excluded from the active FDA NDC Directory. The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Apr 2024. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory. Search the FDA NDC Directory ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0591-5513-01
Product NDC 0591-5513
11-digit billing NDC 00591551301
NCPDP billing unit EA — each (per item)
SPL Set ID 4a15bd91-cbb3-46a8-ab0a-1e153c72d97a
DEA schedule CIV
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status Discontinued
FDA listing status Discontinued by firm (certified through Apr 2024)
Marketing start 1987-11-01
Dosage form TABLET
Substance CARISOPRODOL

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 75100020000305
GPI class Carisoprodol
GCN Seq No 004663
GCN 17912
HICL code 001944
Ingredient (HICL) Carisoprodol
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Midbrain
HIC3 code H6H
Therapeutic class — specific (HIC3) Skeletal Muscle Relaxants
AHFS code 12:20.04.00
AHFS class Centrally Acting Skeletal Muscle Relaxnt
FDB label name CARISOPRODOL 350 MG TABLET
FDB brand name Carisoprodol
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 004663
  • GCN: 17912
  • GPI-14 (Medi-Span): 75100020000305
  • HICL (First Databank): 001944
  • AHFS class code: 12:20.04.00
Why two NDCs? The FDA registers this code as 0591-5513-01 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00591-5513-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name CARISOPRODOL 350 MG TABLET Ingredient Carisoprodol
📖 What it is MedlinePlus · NLM

Carisoprodol is used with rest, physical therapy, and other measures to relax muscles and relieve pain and discomfort caused by strains, sprains, and other muscle injuries. Carisoprodol is in a class of medications called skeletal muscle relaxants. It works by acting in the brain and nervous system to allow the muscles to relax.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It relieves discomfort from sudden, painful muscle and bone problems, like a strain, in adults. It is meant for short use, up to two or three weeks.
  • Take it by mouth, usually three times a day and at bedtime, with or without food. Follow your prescriber's directions and don't use it longer than prescribed.
  • It can. Drowsiness, dizziness, and headache are the most common side effects. Don't drive or do hazardous tasks until you know how it affects you.
  • No, it's best to avoid alcohol. It adds to the sedation. The same goes for benzodiazepines, opioids, and tricyclic antidepressants, so tell me about everything you take.
📖 Read our full Carisoprodol guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.071 $7.12 / 100 tablets
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2021 Apr 2022 Sep 2022 Feb 2024 $0.075 $0.050
▲ Up 20% over the last 15 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00591-5513-01 You're viewing this Main listing 100 TABLET in 1 BOTTLE $0.0712 / ea $7.12 1987-11-01 — Discontinued by firm
00591-5513-05 0591-5513-05 500 TABLET in 1 BOTTLE $0.0712 / ea $35.61 1987-11-01 — Discontinued by firm
00591-5513-10 0591-5513-10 1000 TABLET in 1 BOTTLE $0.0712 / ea $71.21 1987-11-01 — Discontinued by firm
00591-5513-00 0591-5513-00 22200 TABLET in 1 BAG — — — — Active

You're viewing the smallest of 4 pack sizes for this product.

This pack has the lowest per-ea cost of the 3 priced pack sizes ($0.0712 NADAC).

Pack size FAQ

What quantity is in this package?
This is a 100-count package — 100 tablet in 1 bottle.
How does this package differ from NDC 00591-5513-05?
Both are Carisoprodol 350 mg Tablet — the drug itself is identical. This page's package is the 100-count one, while NDC 00591-5513-05 is the 500 tablets package.
What NDC number is used to bill for this package of Carisoprodol 350 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Carisoprodol 350 mg 42543-0700-01 Vensun 100 tablets $0.051 AA FDA listed save 28%
carisoprodol 350 mg 16571-0781-01 Rising 100 tablets $0.071 AA Availability likely save 1%
Carisoprodol 350 mg 50228-0109-01 ScieGen 100 tablets $0.071 AA Availability likely save 1%
Carisoprodol 350 mg 50742-0656-01 Ingenus 100 tablets $0.071 AA Availability likely save 1%
Carisoprodol 350 mg 62135-0241-12 Chartwell 120 tablets $0.071 AA Availability likely save 1%
Carisoprodol Tablets, USP, 350 mg 63561-0127-01 Granulation 100 tablets $0.071 AA Availability likely save 1%
Carisoprodol 350 mg 69367-0420-01 Westminster 100 tablets $0.071 AA Availability likely save 1%
Carisoprodol 350 mg 69584-0111-10 Oxford 100 tablets $0.071 AA Availability likely save 1%
carisoprodol 350 mg 65862-0158-01 Aurobindo 100 tablets $0.071 — FDA listed —
Carisoprodol 350 mgthis 00591-5513-01 Actavis 100 tablets $0.071 — Discontinued —
Soma 350 mg 00037-2001-01 Viatris 100 tablets $11.298 AA Availability likely +15765%
Carisoprodol 350 mg 45865-0233-30 Medsource 30 tablets — AA FDA listed —
Carisoprodol 350 mg 50090-5953-05 A-S 90 tablets — AA FDA listed —
Carisoprodol 350 mg 50090-5955-00 A-S 30 tablets — AA FDA listed —
Carisoprodol 350 mg 52536-0688-10 Wilshire 100 tablets — AA FDA listed —
Carisoprodol 350 mg 60760-0397-90 St. 90 tablets — AA FDA listed —
Carisoprodol 350 mg 61919-0878-60 Direct_Rx 60 tablets — AA FDA listed —
Carisoprodol 350 mg 63629-2416-01 Bryant 100 tablets — AA FDA listed —
Carisoprodol 350 mg 63629-8477-01 Bryant 1000 tablets — AA FDA listed —
Carisoprodol 350 mg 63629-8478-01 Bryant 500 tablets — AA FDA listed —
Carisoprodol 350 mg 63629-8479-01 Bryant 100 tablets — AA FDA listed —
carisoprodol 350 mg 68071-3421-06 NuCare 60 tablets — AA FDA listed —
Carisoprodol 350 mg 68071-5075-03 NuCare 30 tablets — AA FDA listed —
Carisoprodol 350 mg 70518-2800-00 REMEDYREPACK 60 tablets — AA FDA listed —
carisoprodol 350 mg 70518-3792-00 REMEDYREPACK 90 tablets — AA FDA listed —
Carisoprodol 350 mg 71205-0241-20 Proficient 20 tablets — AA FDA listed —
Carisoprodol 350 mg 71205-0339-30 Proficient 30 tablets — AA FDA listed —
Carisoprodol 350 mg 71205-0704-30 Proficient 30 tablets — AA FDA listed —
Carisoprodol 350 mg 71335-1203-00 Bryant 56 tablets — AA FDA listed —
Carisoprodol Tablets, USP, 350 mg 71335-3018-01 Bryant 1000 tablets — AA FDA listed —
carisoprodol 350 mg 71335-9613-00 Bryant 56 tablets — AA FDA listed —
Carisoprodol 350 mg 71335-9621-00 Bryant 56 tablets — AA FDA listed —
Carisoprodol 350 mg 71610-0617-30 Aphena 30 tablets — AA FDA listed —
Carisoprodol 350 mg 71610-0761-30 Aphena 30 tablets — AA FDA listed —
Carisoprodol 350 mg 72162-1524-00 Bryant 1000 tablets — AA FDA listed —
Carisoprodol 350 mg 72162-1928-01 Bryant 100 tablets — AA FDA listed —
Carisoprodol Tablets, USP, 350 mg 72162-2525-00 Bryant 1000 tablets — AA FDA listed —
Carisoprodol 350 mg 72189-0310-30 Directrx 30 tablets — AA FDA listed —
Carisoprodol 350 mg 72189-0386-30 Direct_Rx 30 tablets — AA FDA listed —
Carisoprodol 350 mg 72789-0182-01 PD-Rx 100 tablets — AA FDA listed —
Carisoprodol 350 mg 72789-0190-14 PD-Rx 14 tablets — AA FDA listed —
Carisoprodol Tablets, USP, 350 mg 72789-0477-01 PD-Rx 100 tablets — AA FDA listed —
Carisoprodol 350 mg 76420-0646-01 Asclemed 100 tablets — AA FDA listed —
carisoprodol 350 mg 76420-0853-00 Asclemed 1000 tablets — AA FDA listed —
Carisoprodol 350 mg 80425-0291-01 Advanced 30 tablets — AA FDA listed —
Carisoprodol 350 mg 82868-0062-30 Northwind 30 tablets — AA FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1987
On the market since
Nov 1987
📍
2026
Currently FDA-listed
39 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Carisoprodol inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

We could not link this NDC to a current FDA Structured Product Label. An inactive-ingredient list is therefore not available from this source.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerActavis Pharma, Inc.
Labeler code00591
First marketedNov 1987
DEA scheduleCIV
Product typeDrug For Further Processing
Portfolio324 products on file

More NDCs from Actavis Pharma, Inc. labeler code 00591

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Carisoprodol (matched by generic name) — the program that covers self-administered drugs. 7 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Carisoprodol. CMS lists 2 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$856.8K
Claims incl. refills
64.2K
Beneficiaries
36.6K
Spend / beneficiary
$23.39
Spend / claim
$13.35
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Listed for further processing / repackaging No longer marketed (per FDA listing data)

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Actavis Pharma, Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Does this product come in other package sizes?
Yes — the FDA directory lists 3 other package presentations of this same product, including 500 tablets (00591-5513-05), 1000 tablets (00591-5513-10), 22200 tablets (00591-5513-00). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Actavis Pharma, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00591-5443-01 · Actavis 00591-5543-01 · Actavis →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.